Anti-inflammatory strategies in stroke: A potential therapeutic target

Current Vascular Pharmacology

Volumn 14, Issue 1, 2016, Pages 98-105

  Siniscalchi, Antonio ^a   Iannacchero, Rosario ^b   Anticoli, Sabrina ^c   Pezzella, Francesca Romana ^c   De Sarro, Giovambattista ^d   Gallelli, Luca ^d  

^a Annunziata Hospital   (Italy)

^b PUGLIESE CIACCIO HOSPITAL   (Italy)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Acute stroke; Anti ICAM 1; Antibody; Cytokines; Inflammation; Integrins; Selectins

Indexed keywords

CYTOKINE; ENLIMOMAB; HIGH MOBILITY GROUP B1 PROTEIN; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; PEROXIREDOXIN; SELECTIN; TOLL LIKE RECEPTOR; ANTIINFLAMMATORY AGENT; GLUCOSE; MONOCLONAL ANTIBODY; OXYGEN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN DAMAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); HUMAN; IMMUNOLOGICAL TOLERANCE; NEUTROPHIL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); ANIMAL; INFLAMMATION; METABOLISM; PATHOLOGY; STROKE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BRAIN ISCHEMIA; CYTOKINES; GLUCOSE; HUMANS; INFLAMMATION; OXYGEN; STROKE;

EID: 84949920936     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161113666150923111329     Document Type: Article

References (133)

1. Mehndiratta P, Chapman Smith S, Worrall BB. Etiologic stroke subtypes: updated definition and efficient workup strategies. Curr Treat Options Cardiovasc Med 2015; 17(1): 357.
2. Norrving B, Kissela B. The global burden of stroke and need for a continuum of care. Neurology 2013; 80(3 Suppl 2): S5-12.
3. Muir KW, Tyrrell P, Sattar N, Warburton E. Inflammation and ischaemic stroke. Curr Opin Neurol 2007; 20(3): 334-42.
4. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999; 22(9): 391-7.
5. Chamorro A, Hallenbeck J. The harms and benefits of inflammatory and immune responses in vascular disease. Stroke 2006; 37(2): 291-3.
6. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med 2011; 17(7): 796-808.
7. Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron 2010; 67(2): 181-98.
8. Siniscalchi A, Gallelli L, Malferrari G, et al. Cerebral stroke injury: the role of cytokines and brain inflammation. J Basic Clin Physiol Pharmacol 2014; 25(2): 131-7.
9. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333(24): 1581-7.
10. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359(13): 1317-29.
11. Lansberg MG, Bluhmki E, Thijs VN. Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. Stroke 2009; 40(7): 2438-41.
12. Zhang J, Yang Y, Sun H, Xing Y. Hemorrhagic transformation after cerebral infarction: current concepts and challenges. Ann Transl Med 2014; 2(8): 81.
13. Huang J, Upadhyay UM, Tamargo RJ. Inflammation in stroke and focal cerebral ischemia. Surg Neurol 2006; 66(3): 232-45.
14. Sughrue ME, Mehra A, Connolly ES, Jr., D'Ambrosio AL. Antiadhesion molecule strategies as potential neuroprotective agents in cerebral ischemia: a critical review of the literature. Inflamm Res 2004; 53(10): 497-508.
15. Zhang R, Chopp M, Zhang Z, Jiang N, Powers C. The expression of P-and E-selectins in three models of middle cerebral artery occlusion. Brain Res 1998; 785(2): 207-14.
16. Chapman KZ, Ge R, Monni E, et al. Inflammation without neuronal death triggers striatal neurogenesis comparable to stroke. Neurobiol Dis 2015; 83: 1-15.
17. Kozuka K, Kohriyama T, Nomura E, Ikeda J, Kajikawa H, Nakamura S. Endothelial markers and adhesion molecules in acute ischemic stroke--sequential change and differences in stroke subtype. Atherosclerosis 2002; 161(1): 161-8.
18. Mussack T, Biberthaler P, Gippner-Steppert C, et al. Early cellular brain damage and systemic inflammatory response after cardiopulmonary resuscitation or isolated severe head trauma: a comparative pilot study on common pathomechanisms. Resuscitation 2001; 49(2): 193-9.
19. Latour LL, Kang DW, Ezzeddine MA, Chalela JA, Warach S. Early blood-brain barrier disruption in human focal brain ischemia. Ann Neurol 2004; 56(4): 468-77.
20. Kim JY, Kawabori M, Yenari MA. Innate inflammatory responses in stroke: mechanisms and potential therapeutic targets. Curr Med Chem 2014; 21(18): 2076-97.
21. Yilmaz G, Vital S, Yilmaz CE, Stokes KY, Alexander JS, Granger DN. Selectin-mediated recruitment of bone marrow stromal cells in the postischemic cerebral microvasculature. Stroke 2011; 42(3): 806-11.
22. Yu CY, Ng G, Liao P. Therapeutic antibodies in stroke. Transl Stroke Res 2013; 4(5): 477-83.
23. Frijns CJ, Kappelle LJ. Inflammatory cell adhesion molecules in ischemic cerebrovascular disease. Stroke 2002; 33(8): 2115-22.
24. Serra R, Grande R, Montemurro R, et al. The role of matrix metalloproteinases and neutrophil gelatinase-associated lipocalin in central and peripheral arterial aneurysms. Surgery 2015; 157(1): 155-62.
25. Serra R, Grande R, Gallelli L, et al. Carotid body paragangliomas and matrix metalloproteinases. Ann Vasc Surg 2014; 28(7): 1665-70.
26. de Franciscis S, Mastroroberto P, Gallelli L, Buffone G, Montemurro R, Serra R. Increased plasma levels of metalloproteinase-9 and neutrophil gelatinase-associated lipocalin in a rare case of multiple artery aneurysm. Ann Vasc Surg 2013; 27(8): 1185.e5-e7.
27. Serra R, Gallelli L, Buffone G, et al. Doxycycline speeds up healing of chronic venous ulcers. Int Wound J 2015; 12(2): 179-84.
28. Slevin M, Krupinski J, Rovira N, et al. Identification of proangiogenic markers in blood vessels from stroked-affected brain tissue using laser-capture microdissection. BMC Genomics 2009; 10: 113.
29. Rock KL, Latz E, Ontiveros F, Kono H. The sterile inflammatory response. Annu Rev Immunol 2010; 28: 321-42.
30. Matsuo Y, Kihara T, Ikeda M, Ninomiya M, Onodera H, Kogure K. Role of neutrophils in radical production during ischemia and reperfusion of the rat brain: effect of neutrophil depletion on extracellular ascorbyl radical formation. J Cereb Blood Flow Metab 1995; 15(6): 941-7.
31. Matsuo Y, Onodera H, Shiga Y, et al. Correlation between myeloperoxidase-quantified neutrophil accumulation and ischemic brain injury in the rat. Effects of neutrophil depletion. Stroke 1994; 25(7): 1469-75.
32. Fossati S, Chiarugi A. Relevance of high-mobility group protein box 1 to neurodegeneration. Int Rev Neurobiol 2007; 82: 137-48.
33. Moraga A, Pradillo JM, Cuartero MI, et al. Toll-like receptor 4 modulates cell migration and cortical neurogenesis after focal cerebral ischemia. FASEB J 2014; 28(11): 4710-8.
34. Tang SC, Arumugam TV, Xu X, et al. Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci USA 2007; 104(34): 13798-803.
35. Hyakkoku K, Hamanaka J, Tsuruma K, et al. Toll-like receptor 4 (TLR4), but not TLR3 or TLR9, knock-out mice have neuroprotective effects against focal cerebral ischemia. Neuroscience 2010; 171(1): 258-67.
36. Cao CX, Yang QW, Lv FL, Cui J, Fu HB, Wang JZ. Reduced cerebral ischemia-reperfusion injury in Toll-like receptor 4 deficient mice. Biochem Biophys Res Commun 2007; 353(2): 509-14.
37. Caso JR, Pradillo JM, Hurtado O, Lorenzo P, Moro MA, Lizasoain I. Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation 2007; 115(12): 1599-608.
38. Caso JR, Pradillo JM, Hurtado O, Leza JC, Moro MA, Lizasoain I. Toll-like receptor 4 is involved in subacute stress-induced neuroinflammation and in the worsening of experimental stroke. Stroke 2008; 39(4): 1314-20.
39. Bodhankar S, Chen Y, Lapato A, et al. PD-L1 Monoclonal Antibody Treats Ischemic Stroke by Controlling Central Nervous System Inflammation. Stroke 2015; 46(10): 2926-34.
40. Holloway PM, Durrenberger PF, Trutschl M, et al. Both MC1 and MC3 Receptors Provide Protection From Cerebral Ischemia-Reperfusion-Induced Neutrophil Recruitment. Arterioscler Thromb Vasc Biol 2015; 35(9): 1936-44.
41. Zhu Y, Yang GY, Ahlemeyer B, et al. Transforming growth factorbeta 1 increases bad phosphorylation and protects neurons against damage. J Neurosci 2002; 22(10): 3898-909.
42. Smith CJ, Lawrence CB, Rodriguez-Grande B, Kovacs KJ, Pradillo JM, Denes A. The immune system in stroke: clinical challenges and their translation to experimental research. J Neuroimmune Pharmacol 2013; 8(4): 867-87.
43. Posada-Duque RA, Barreto GE, Cardona-Gomez GP. Protection after stroke: cellular effectors of neurovascular unit integrity. Front Cell Neurosci 2014; 8: 231.
44. Deftereos S, Angelidis C, Bouras G, et al. Innate immune inflammatory response in the acutely ischemic myocardium. Med Chem 2014; 10(7): 653-62.
45. Banwell V, Sena ES, Macleod MR. Systematic review and stratified meta-analysis of the efficacy of interleukin-1 receptor antagonist in animal models of stroke. J Stroke Cerebrovasc Dis 2009; 18(4): 269-76.
46. Zeng L, Wang Y, Liu J, et al. Pro-inflammatory cytokine network in peripheral inflammation response to cerebral ischemia. Neurosci Lett 2013; 548: 4-9.
47. Caso JR, Moro MA, Lorenzo P, Lizasoain I, Leza JC. Involvement of IL-1beta in acute stress-induced worsening of cerebral ischaemia in rats. Eur Neuropsychopharmacol 2007; 17(9): 600-7.
48. Boutin H, LeFeuvre RA, Horai R, Asano M, Iwakura Y, Rothwell NJ. Role of IL-1alpha and IL-1beta in ischemic brain damage. J Neurosci 2001; 21(15): 5528-34.
49. Deroide N, Li X, Lerouet D, et al. MFGE8 inhibits inflammasomeinduced IL-1beta production and limits postischemic cerebral injury. J Clin Invest 2013; 123(3): 1176-81.
50. Clark WM, Rinker LG, Lessov NS, Hazel K, Eckenstein F. Time course of IL-6 expression in experimental CNS ischemia. Neurol Res 1999; 21(3): 287-92.
51. Acalovschi D, Wiest T, Hartmann M, et al. Multiple levels of regulation of the interleukin-6 system in stroke. Stroke 2003; 34(8): 1864-9.
52. Vila N, Castillo J, Davalos A, Chamorro A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 2000; 31(10): 2325-9.
53. Gallelli L, Falcone D, Pelaia G, et al. Interleukin-6 receptor superantagonist Sant7 inhibits TGF-beta-induced proliferation of human lung fibroblasts. Cell Prolif 2008; 41(3): 393-407.
54. Clark WM, Rinker LG, Lessov NS, et al. Lack of interleukin-6 expression is not protective against focal central nervous system ischemia. Stroke 2000; 31(7): 1715-20.
55. Chen WY, Chang MS. IL-20 is regulated by hypoxia-inducible factor and up-regulated after experimental ischemic stroke. J Immunol 2009; 182(8): 5003-12.
56. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87(6): 2095-147.
57. Chiba T, Umegaki K. Pivotal roles of monocytes/macrophages in stroke. Mediators Inflamm 2013; 2013: 759103.
58. Yamasaki Y, Matsuo Y, Zagorski J, et al. New therapeutic possibility of blocking cytokine-induced neutrophil chemoattractant on transient ischemic brain damage in rats. Brain Res 1997; 759(1): 103-11.
59. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. The J Exp Med 1991; 174(5): 1209-20.
60. Geng Y, Gulbins E, Altman A, Lotz M. Monocyte deactivation by interleukin 10 via inhibition of tyrosine kinase activity and the Ras signaling pathway. Proc Natl Acad Sci USA 1994; 91(18): 8602-6.
61. Tarkowski E, Rosengren L, Blomstrand C, et al. Intrathecal release of pro-and anti-inflammatory cytokines during stroke. Clin Exp Immunol 1997; 110(3): 492-9.
62. Bodhankar S, Chen Y, Vandenbark AA, Murphy SJ, Offner H. IL-10-producing B-cells limit CNS inflammation and infarct volume in experimental stroke. Metab Brain Dis 2013; 28(3): 375-86.
63. Lakhan SE, Kirchgessner A, Hofer M. Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J Transl Med 2009; 7: 97.
64. Spera PA, Ellison JA, Feuerstein GZ, Barone FC. IL-10 reduces rat brain injury following focal stroke. Neurosci Lett 1998; 251(3): 189-92.
65. Denes A, Humphreys N, Lane TE, Grencis R, Rothwell N. Chronic systemic infection exacerbates ischemic brain damage via a CCL5 (regulated on activation, normal T-cell expressed and secreted)-mediated proinflammatory response in mice. J Neurosci 2010; 30(30): 10086-95.
66. Jiang HR, Milovanovic M, Allan D, et al. IL-33 attenuates EAE by suppressing IL-17 and IFN-gamma production and inducing alternatively activated macrophages. Eur J Immunol 2012; 42(7): 1804-14.
67. Pomeshchik Y, Kidin I, Korhonen P, et al. Interleukin-33 treatment reduces secondary injury and improves functional recovery after contusion spinal cord injury. Brain Behav Immun 2015; 44: 68-81.
68. Korhonen P, Kanninen KM, Lehtonen S, et al. Immunomodulation by interleukin-33 is protective in stroke through modulation of inflammation. Brain Behav Immun 2015; 49: 322-36.
69. Abe K, Yuki S, Kogure K. Strong attenuation of ischemic and postischemic brain edema in rats by a novel free radical scavenger. Stroke 1988; 19(4): 480-5.
70. Zhang N, Komine-Kobayashi M, Tanaka R, Liu M, Mizuno Y, Urabe T. Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain. Stroke 2005; 36(10): 2220-5.
71. Potey C, Ouk T, Petrault O, et al. Early treatment with atorvastatin exerts parenchymal and vascular protective effects in experimental cerebral ischemia. Br J Pharmacol 2015; 172(21): 5188-98.
72. Silva BC, de Miranda AS, Rodrigues FG, et al. The 5-lipoxygenase (5-LOX) inhibitor zileuton reduces inflammation and infarct size with improvement in neurological outcome following cerebral ischemia. Curr Neurovasc Res 2015; 12(4): 398-403.
73. Sun YY, Morozov YM, Yang D, et al. Synergy of combined tPAedaravone therapy in experimental thrombotic stroke. PloS One 2014; 9(6): e98807.
74. Tiebosch IA, Crielaard BJ, Bouts MJ, et al. Combined treatment with recombinant tissue plasminogen activator and dexamethasone phosphate-containing liposomes improves neurological outcome and restricts lesion progression after embolic stroke in rats. J Neurochem 2012; 123(Suppl 2): 65-74.
75. Elewa HF, Hilali H, Hess DC, Machado LS, Fagan SC. Minocycline for short-term neuroprotection. Pharmacotherapy 2006; 26(4): 515-21.
76. Buller KM, Carty ML, Reinebrant HE, Wixey JA. Minocycline: a neuroprotective agent for hypoxic-ischemic brain injury in the neonate? J Neurosci Res 2009; 87(3): 599-608.
77. Guo J, Chen Q, Tang J, et al. Minocycline-induced attenuation of iron overload and brain injury after experimental germinal matrix hemorrhage. Brain Res 2015; 1594: 115-24.
78. Zhao F, Hua Y, He Y, Keep RF, Xi G. Minocycline-induced attenuation of iron overload and brain injury after experimental intracerebral hemorrhage. Stroke 2011; 42(12): 3587-93.
79. Huang CY, Chen YL, Li AH, Lu JC, Wang HL. Minocycline, a microglial inhibitor, blocks spinal CCL2-induced heat hyperalgesia and augmentation of glutamatergic transmission in substantia gelatinosa neurons. J Neuroinflammation 2014; 11: 7.
80. Yang F, Zhou L, Wang D, Wang Z, Huang QY. Minocycline ameliorates hypoxia-induced blood-brain barrier damage by inhibition of HIF-1alpha through SIRT-3/PHD-2 degradation pathway. Neuroscience 2015; 304: 250-9.
81. Zhang BJ, Men XJ, Lu ZQ, Li HY, Qiu W, Hu XQ. Splenectomy protects experimental rats from cerebral damage after stroke due to anti-inflammatory effects. Chin Med J (Engl) 2013; 126(12): 2354-60.
82. Manwani B, Liu F, Scranton V, Hammond MD, Sansing LH, McCullough LD. Differential effects of aging and sex on stroke induced inflammation across the lifespan. Exp Neurol 2013; 249: 120-31.
83. Banerjee A, Wang J, Bodhankar S, Vandenbark AA, Murphy SJ, Offner H. Phenotypic changes in immune cell subsets reflect increased infarct volume in male vs. female mice. Transl Stroke Res 2013; 4(5): 554-63.
84. Dotson AL, Wang J, Saugstad J, Murphy SJ, Offner H. Splenectomy reduces infarct volume and neuroinflammation in male but not female mice in experimental stroke. J Neuroimmunol 2015; 278: 289-98.
85. Ishikawa M, Cooper D, Arumugam TV, Zhang JH, Nanda A, Granger DN. Platelet-leukocyte-endothelial cell interactions after middle cerebral artery occlusion and reperfusion. J Cereb Blood Flow Metab 2004; 24(8): 907-15.
86. Ishikawa M, Cooper D, Russell J, et al. Molecular determinants of the prothrombogenic and inflammatory phenotype assumed by the postischemic cerebral microcirculation. Stroke 2003; 34(7): 1777-82.
87. Jin AY, Tuor UI, Rushforth D, et al. Reduced blood brain barrier breakdown in P-selectin deficient mice following transient ischemic stroke: a future therapeutic target for treatment of stroke. BMC Neurosci 2010; 11: 12.
88. Connolly ES, Winfree CJ, Prestigiacomo CJ, et al. Exacerbation of cerebral injury in mice that express the P-selectin gene-Identification of P-selectin blockade as a new target for the treatment of stroke. Circ Res 1997; 81(3): 304-10.
89. Goussev AV, Zhang ZG, Anderson DC, Chopp M. P-selectin antibody reduces hemorrhage and infarct volume resulting from MCA occlusion in the rat. J Neurol Sci 1998; 161(1): 16-22.
90. Suzuki H, Abe K, Tojo SJ, et al. Reduction of ischemic brain injury by anti-P-selectin monoclonal antibody after permanent middle cerebral artery occlusion in rat. Neurol Res 1999; 21(3): 269-76.
91. Huang J, Choudhri TF, Winfree CJ, et al. Postischemic cerebrovascular E-selectin expression mediates tissue injury in murine stroke. Stroke 2000; 31(12): 3047-53.
92. Yenari MA, Sun GH, Kunis DM, Onley D, Vexler V. L-selectin inhibition does not reduce injury in a rabbit model of transient focal cerebral ischemia. Neurol Res 2001; 23(1): 72-8.
93. Ruehl ML, Orozco JA, Stoker MB, McDonagh PF, Coull BM, Ritter LS. Protective effects of inhibiting both blood and vascular selectins after stroke and reperfusion. Neurol Res 2002; 24(3): 226-32.
94. Bednar MM, Gross CE, Russell SR, et al. Humanized anti-Lselectin monoclonal antibody DREG200 therapy in acute thromboembolic stroke. Neurol Res 1998; 20(5): 403-8.
95. Zhang RL, Chopp M, Jiang N, et al. Anti-intercellular adhesion molecule-1 antibody reduces ischemic cell damage after transient but not permanent middle cerebral artery occlusion in the Wistar rat. Stroke 1995; 26(8): 1438-42; discussion 43.
96. Bowes MP, Rothlein R, Fagan SC, Zivin JA. Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy. Neurology 1995; 45(4): 815-9.
97. Zhang RL, Zhang ZG, Chopp M. Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain. Stroke 1999; 30(3): 624-9.
98. Weber C, Springer TA. Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaIIbbeta3 and stimulated by platelet-activating factor. J Clin Invest 1997; 100(8): 2085-93.
99. Simon DI, Chen Z, Xu H, et al. Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med 2000; 192(2): 193-204.
100. Chopp M, Zhang RL, Chen H, Li Y, Jiang N, Rusche JR. Postischemic administration of an anti-Mac-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in rats. Stroke 1994; 25(4): 869-75; discussion 75-6.
101. Kikuchi K, Tanaka E, Murai Y, Tancharoen S. Clinical trials in acute ischemic stroke. CNS Drugs 2014; 28(10): 929-38.
102. Kitagawa K, Matsumoto M, Hori M. Cerebral ischemia in 5-lipoxygenase knockout mice. Brain Res 2004; 1004(1-2): 198-202.
103. Iadecola C, Zhang F, Xu S, Casey R, Ross ME. Inducible nitric oxide synthase gene expression in brain following cerebral ischemia. J Cereb Blood Flow Metab 1995; 15(3): 378-84.
104. Iadecola C, Zhang F, Xu X. Inhibition of inducible nitric oxide synthase ameliorates cerebral ischemic damage. Am J Physiol 1995; 268(1 Pt 2): R286-92.
105. Smith CJ, Emsley HC, Udeh CT, et al. Interleukin-1 receptor antagonist reverses stroke-associated peripheral immune suppression. Cytokine 2012; 58(3): 384-9.
106. Gueorguieva I, Clark SR, McMahon CJ, et al. Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage. Br J Clin Pharmacol 2008; 65(3): 317-25.
107. Worrall BB, Brott TG, Brown RD, Jr., et al. IL1RN VNTR polymorphism in ischemic stroke: analysis in 3 populations. Stroke 2007; 38(4): 1189-96.
108. Emsley HC, Smith CJ, Georgiou RF, et al. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry 2005; 76(10): 1366-72.
109. Tobinick E, Kim NM, Reyzin G, Rodriguez-Romanacce H, DePuy V. Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept. CNS Drugs 2012; 26(12): 1051-70.
110. Huang Z, Yin Q, Sun W, et al. Microbleeds in ischemic stroke are associated with lower serum adiponectin and higher soluble Eselectin levels. J Neurol Sci 2013; 334(1-2): 83-7.
111. Mocco J, Choudhri T, Huang J, et al. HuEP5C7 as a humanized monoclonal anti-E/P-selectin neurovascular protective strategy in a blinded placebo-controlled trial of nonhuman primate stroke. Circ Res 2002; 91(10): 907-14.
112. Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology 2001; 57(8): 1428-34.
113. Becker KJ. Anti-leukocyte antibodies: LeukArrest (Hu23F2G) and Enlimomab (R6.5) in acute stroke. Curr Med Res Opin 2002; 18(Suppl 2): s18-22.
114. Krams M, Lees KR, Hacke W, Grieve AP, Orgogozo JM, Ford GA. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke 2003; 34(11): 2543-8.
115. Campanella M, Sciorati C, Tarozzo G, Beltramo M. Flow cytometric analysis of inflammatory cells in ischemic rat brain. Stroke 2002; 33(2): 586-92.
116. Caimi G, Canino B, Ferrara F, et al. Granulocyte integrins before and after activation in acute ischaemic stroke. J Neurol Sci 2001; 186(1-2): 23-6.
117. Kamel H, Iadecola C. Brain-immune interactions and ischemic stroke: clinical implications. Arch Neurol 2012; 69(5): 576-81.
118. Friedrichs K, Klinke A, Baldus S. Inflammatory pathways underlying atrial fibrillation. Trends Mol Med 2011; 17(10): 556-63.
119. da Cunha AA, Ferreira AG, Loureiro SO, et al. Chronic hyperhomocysteinemia increases inflammatory markers in hippocampus and serum of rats. Neurochem Res 2012; 37(8): 1660-9.
120. Siniscalchi A, Mancuso F, Gallelli L, Ibbadu GF, Mercuri NB, De Sarro G. Increase in plasma homocysteine levels induced by drug treatments in neurologic patients. Pharmacol Res 2005; 52(5): 367-75.
121. Siniscalchi A, Gallelli L, Mercuri NB, Ibbadu GF, De Sarro G. Role of lifestyle factors on plasma homocysteine levels in Parkison's disease patients treated with levodopa. Nutr Neurosci 2006; 9(1-2): 11-6.
122. Sierra C, Coca A, Schiffrin EL. Vascular mechanisms in the pathogenesis of stroke. Curr Hypertens Rep 2011; 13(3): 200-7.
123. Xing Y, Guo ZN, Yan S, Jin H, Wang S, Yang Y. Increased globulin and its association with hemorrhagic transformation in patients receiving intra-arterial thrombolysis therapy. Neurosci Bull 2014; 30(3): 469-76.
124. Audebert HJ, Pellkofer TS, Wimmer ML, Haberl RL. Progression in lacunar stroke is related to elevated acute phase parameters. Eur Neurol 2004; 51(3): 125-31.
125. Audebert HJ, Rott MM, Eck T, Haberl RL. Systemic inflammatory response depends on initial stroke severity but is attenuated by successful thrombolysis. Stroke 2004; 35(9): 2128-33.
126. Audebert HJ, Sobesky J. Stroke: 'Time is brain' after stroke, regardless of age and severity. Nat Rev Neurol 2014; 10(12): 675-6.
127. Zhu Z, Fu Y, Tian D, et al. Combination of an immune modulator fingolimod with alteplase in acute ischemic stroke: a pilot trial. Circulation 2015; 132(12): 1104-12.
128. Pelaia G, Gallelli L, Romeo P, et al. Omalizumab decreases exacerbation frequency, oral intake of corticosteroids and peripheral blood eosinophils in atopic patients with uncontrolled asthma. Int J Clin Pharmacol Ther 2011; 49(12): 713-21.
129. Pelaia G, Vatrella A, Busceti MT, Gallelli L, Terracciano R, Maselli R. Anti-IgE therapy with omalizumab for severe asthma: current concepts and potential developments. Curr Drug Targets 2015; 16(2): 171-8.
130. Kennedy WP, Simon J, Offutt C, et al. Efficacy and safety of pateclizumab (anti-Lymphotoxin-inverted question mark) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study). Arthritis Res Ther 2014; 16(5): 467.
131. Leonardi CL, Romiti R, Tebbey PW. Ten years on: the impact of biologics on the practice of dermatology. Dermatol Clin 2015; 33(1): 111-25.
132. Desautels D, Harlos C, Czaykowski P. The advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer. J Carcinog 2014; 13: 13.
133. Dubey D, Kieseier BC, Hartung HP, Hemmer B, Miller-Little WA, Stuve O. Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates. Expert Rev Clin Immunol 2015; 11(1): 93-108.